A phase Ⅰ dose escalation study of BIBW2992 , an irreversible dual EFFR / ER2 receptor tyrosine kinase inhibitor , in a continuous schedule in patients with advanced solid tumors .Planchard D . Interim results of a phase Ⅱ study of the BRAF inhibitor ( BR ......